Mioara Larion, Ph.D.
Building 37, Roon 1136A
Bethesda, MD 20892
Glioblastoma multiforme (GBMs) is the most common and aggressive brain tumor. Despite years of research and clinical trials, the median survival remains about 14.6 months, underlying an urgent need for better treatment. Although profiling of mutations, gene and protein expressions have contributed significantly to the understanding of tumor biology, little is known about the metabolic signatures of different GBM types. Metabolomics report on the set of metabolites present within a cell, tissue or organism by identifying and quantifying the steady state cellular metabolites. Since metabolic reprograming is emerging as a hallmark of cancer, a detailed characterization of patient’s tumor metabolic state together with the results of other omics has the potential to provide a better understanding of tumorigenesis. Metabolomics can also be used as a cancer diagnosis tool since specific metabolic signatures correlate with different glioblastoma subtypes therefore helping in the characterization of tumor stage, type or prognosis. Most importantly a comprehensive analysis of differentially expressed metabolites between normal and cancer cells offers avenues towards identification of potential pathways to be targeted for therapeutics.
My laboratory is focused on understanding the metabolic changes in brain tumors such as GBMs. In particular, we are interested in revealing the metabolic alterations of isocitrate dehydrogenase (IDH1)-mutated GBMs and in exploiting these deregulations for therapeutic applications. We will identify and quantify metabolic changes in GBMs using mass spectrometry and nuclear magnetic resonance (MRI) spectroscopy-based metabolomics. In addition, using specific isotope labeling and 13C-hyperpolarized MRI, we will track metabolic fluxes in the pursuit of the following goals: 1) Describe the metabolic flux in patients with glioblastoma containing or not an IDH mutation. 2) Identify and quantify novel metabolic changes in urine, blood, cerebrospinal fluid and brain tissue of patients with GBMs. 3) Produce patient-derived xenographs in mice for further metabolomics characterization. 4) Identify and quantify novel metabolic changes in patient-derived GBM cells expressing endogenous or exogenous IDH mutations.
Another area of my laboratory is to discover and develop novel therapeutics for glioblastoma patients with IDH mutation. Variants of IDH are identified in more than 80% of glioblastomas (GBMs), more than 20% of acute myeloid leukemias (AMLs), neurometabolic disorders and other types of cancers. Although specific inhibitors of D-2HG formation by variant-IDH have been identified, they targeted a single variant of IDH, potentially limiting their use in treating the many other variant-IDH-associated tumors. Cancer-associated somatic mutations in IDH lead to accumulation of D-2HG (up to 30 mM), which is normally kept at low concentrations (~10 μM) in healthy cells by the housekeeping enzyme D-2Hydrohyglutarate dehydrogenase (D-2HGDH). D-2HG inhibits -keto dependent dioxygenases, which are involved in epigenetic modulation of gene expression. Deregulating of these epigenetic controls is thought to lead to tumorigenesis. We are interested in discovering new ways to decrease D-2HG concentration in vivo via it’s recycling to -ketoglutarate. Our aim is to screen and characterize activators of D-2HGDH using a combination of biophysical techniques.
Dr. Mioara Larion received her B.Sc. in Biochemistry from Cuza University, Lasi, Romania in 2002. She moved to Florida State University where she received a M.Sc. in Biophysics in 2005 working on saturation transfer electron paramagnetic resonance methods and their sensitivity to molecular motion upon increasing the field. In 2009, Dr. Larion received her Ph.D. in Biochemistry working on divergent evolution of function in bacterial kinases and the origin of kinetic cooperativity in human pancreatic glucokinase in the laboratory of Prof. Brian Miller. After obtaining her Ph.D in 2009, she was awarded the AHA postdoctoral fellowship to work with Prof. Rafael Brüschweiler on biophysical characterization of glucokinase and PHHI-like variants. Her work helped understand the mechanism of glucokinase’s activation for design of better anti-diabetic therapeutics. Her major interest is in metabolomics of brain tumors.
Whittington AC, Larion M, Bowler JM, Ramsey KM, Brüschweiler R, Miller BG. Dual allosteric activation mechanisms in monomeric human glucokinase. Proc Natl Acad Sci U S A. 2015;112(37):11553-8.
Larion M, Hansen AL, Zhang F, Bruschweiler-Li L, Tugarinov V, Miller BG, Brüschweiler R. Kinetic Cooperativity in Human Pancreatic Glucokinase Originates from Millisecond Dynamics of the Small Domain. Angew Chem Int Ed Engl. 2015;54(28):8129-32.
Larion M, Salinas RK, Bruschweiler-Li L, Miller BG, Brüschweiler R. Order-disorder transitions govern kinetic cooperativity and allostery of monomeric human glucokinase. PLoS Biol. 2012;10(12):e1001452.
Larion M, Salinas RK, Bruschweiler-Li L, Brüschweiler R, Miller BG. Direct evidence of conformational heterogeneity in human pancreatic glucokinase from high-resolution nuclear magnetic resonance. Biochemistry. 2010;49(37):7969-71.
Related Scientific Focus Areas
Molecular Biology and Biochemistry
This page was last updated on June 15th, 2017